Clinical Trial: Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial

U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07420790) titled 'Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial' on Feb. 05.

Brief Summary: To better delineate the contribution of VEN-DEC to the treatment of AML patients aged between >= 60 and < 75 years and deemed fit for Allo-HSCT, real-world data on a patient-level basis will be collected and utilized to generate a matched control cohort of same AML patients treated with intensive chemotherapy.

In addittion, to further validate the efficacy of the VEN-DEC treatment app...